Alpine Immune Sciences Inc (ALPN) - News Archive

Showing 4 of 4 results.

Alpine Immune Sciences Unveils Exciting Breakthroughs in Lupus and Glomerulonephritis Treatment with Povetacicept and Acazicolcept

Alpine Immune Sciences Presents Promising Translational Data on Povetacicept and Acazicolcept for the Treatment of Lupus and Glomerulonephritis Alpine Immune Sciences, a leading clinical-stage immunotherapy company, rec...

Mar 21, 2024 • Major Pharmaceutical Preparations Industry Product Service News NASDAQ

Alpine Immune Sciences Strengthens Partnership with AbbVie and Achieves Impressive Revenue Growth Amidst Pandemic Challenges

Alpine Immune Sciences Updates License Agreement with AbbVie and Demonstrates Revenue GrowthSeattle-based immunotherapy company, Alpine Immune Sciences, has announced an amendment to its option and license agreement wit...

Dec 21, 2023 • Major Pharmaceutical Preparations Industry Business Update NASDAQ

Alpine Immune Sciences Showcases Promising Translational Data for Acazicolcept in Systemic Lupus Erythematosus at ACR Convergence 2023

Alpine Immune Sciences Inc, a renowned clinical-stage immunotherapy company, recently presented groundbreaking translational data for its innovative treatment, acazicolcept (ALPN-101), in the field of systemic lupus ery...

Nov 13, 2023 Product Service News NASDAQ

Alpine Immune Sciences Presents Promising Clinical Data on Povetacicept for Autoimmune Glomerulonephritis at ASN Kidney Week 2023

Seattle-based biopharmaceutical company, Alpine Immune Sciences, is making waves in the field of immunotherapy with their groundbreaking treatment, povetacicept. The company recently presented the first set of clinical...

Nov 2, 2023 Product Service News NASDAQ